Nuwellis is an emerging medical technology company committed to delivering integrated solutions for adult and paediatric patients with cardiorenal conditions, developing technologies for care across the entire heart-kidney continuum. Mike McCormick: Nuwellis is a Nasdaq-listed medical technology company focused on improving the care of patients suffering from fluid overload. There is also greater appreciation that fluid overload is not just a symptom, but a major driver of poor outcomes, hospitalizations and treatment complexity. McCormick: One of the biggest trends we’re seeing is a shift toward earlier, more precise management of fluid overload. At Nuwellis, we believe this evolution creates an opportunity to build a broader cardiorenal care platform.